title: Aliskiren - a promising strategy for ovarian ischemia/reperfusion injury protection in rats via RAAS.
abstract: The aim of this study was to evaluate the effects of aliskiren, direct renin inhibitor, as an antioxidant and tissue protective agent and evaluate the molecular, biochemical, and histopathological changes in experimental ischemia and ischemia/reperfusion injury in rat ovaries. Forty-eight female rats were randomly divided into eight groups: in Group 1, only sham operation was performed. Group 2 received 100 mg/kg aliskiren and sham operated. In Group 3, 3 h-period of bilateral ovarian ischemia was applied. Group 4 received a 3-h period of ischemia followed by 3 h of reperfusion. Groups 5 and 6 received 50 and 100 mg/kg, respectively, of aliskiren and bilateral ovarian ischemia was applied (after a 3-h period of ischemia, both ovaries were surgically removed). To Groups 7 and 8, 50 and 100 mg/kg of aliskiren were administered, respectively, and the induction of ischemia was performed. At the end of a 3-h period of ischemia, bilateral vascular clips were removed, and 3 h of reperfusion continued. After the experiments, IL-1β, IL-6, TNF-α, and iNOS mRNA expressions and SOD, GSH, MDA, renin, and angiotensin-II levels were determined and histopathological changes were examined in rat ovaries. Aliskiren treatment normalized excessive changes in cytokine and oxidative stress markers in both ischemia and ischemia/reperfusion injury. Histopathologically, treatment with aliskiren ameliorated the development of ischemia and/or ischemia/reperfusion tissue injury. This study concluded that aliskiren treatment is effective in reversing ischemia and/or ischemia/reperfusion induced ovary damage via the improvement of oxidative stress, reduction of inflammation, and suppression of the renin-angiotensin aldosterone system.
authors.affiliation: a Department of Biochemistry , Faculty of Pharmacy, Ataturk University , Erzurum , Turkey.
authors.forename: Yasin
authors.initials: Y
authors.lastname: Bayir
authors.affiliation: b Department of Pharmacology , Faculty of Medicine, Ataturk University , Erzurum , Turkey.
authors.forename: Elif
authors.initials: E
authors.lastname: Cadirci
authors.affiliation: c Department of Pharmacology , Faculty of Pharmacy, Ataturk University , Erzurum , Turkey.
authors.forename: Beyzagul
authors.initials: B
authors.lastname: Polat
authors.affiliation: a Department of Biochemistry , Faculty of Pharmacy, Ataturk University , Erzurum , Turkey.
authors.forename: Nurcan
authors.initials: N
authors.lastname: Kilic Baygutalp
authors.affiliation: b Department of Pharmacology , Faculty of Medicine, Ataturk University , Erzurum , Turkey.
authors.forename: Abdulmecit
authors.initials: A
authors.lastname: Albayrak
authors.affiliation: d Department of Pharmacology , Faculty of Veterinary, Ataturk University , Erzurum , Turkey.
authors.forename: Emre
authors.initials: E
authors.lastname: Karakus
authors.affiliation: e Department of Biochemistry , Faculty of Pharmacy, Agri Ibrahim CecenUniversity , Agri , Turkey.
authors.forename: Harun
authors.initials: H
authors.lastname: Un
authors.affiliation: f Department of Medical Biochemistry , Faculty of Medicine, Ataturk University , Erzurum , Turkey.
authors.forename: Mevlut Sait
authors.initials: MS
authors.lastname: Keles
authors.affiliation: f Department of Medical Biochemistry , Faculty of Medicine, Ataturk University , Erzurum , Turkey.
authors.forename: Fatma Betul
authors.initials: FB
authors.lastname: Kocak Ozgeris
authors.affiliation: g Department of Histology and Embryology , Faculty of Medicine, Kafkas University , Kars , Turkey , and.
authors.forename: Erdem
authors.initials: E
authors.lastname: Toktay
authors.affiliation: h Department of Obstetrics and Gynecology , Education and Research Hospital , Antalya , Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Karaca
authors.affiliation: b Department of Pharmacology , Faculty of Medicine, Ataturk University , Erzurum , Turkey.
authors.forename: Zekai
authors.initials: Z
authors.lastname: Halici
mesh_terms: D000577:Amides / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005650:Fumarates / Q000008:administration & dosage / Q000494:pharmacology*; D007511:Ischemia / Q000517:prevention & control*; D010049:Ovarian Diseases / Q000517:prevention & control*; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012084:Renin-Angiotensin System / Q000187:drug effects*; D015427:Reperfusion Injury / Q000517:prevention & control*
chemical_list: D000577:Amides; D005650:Fumarates; D020011:Protective Agents; C446481:aliskiren
keywords: Aliskiren; ischemia; ovary; oxidative stress; rat; reperfusion